European Pharmaceutical Review

OCTOBER 7, 2022

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 The rising requirement for small-scale and encapsulated manufacturing processes necessary to assemble these products make it challenging for many pharmaceutical companies to alter their currently installed capacity.

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

AUGUST 17, 2022

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceutical companies globally are significantly investing in R&D. percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide.

Compounding 96

Compounding Pharmaceutical Companies Pharmaceutical Companies 96

European Pharmaceutical Review

APRIL 3, 2024

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 percent between 2022-2030. Yet large companies are set to expand the market at a higher CAGR of 9.1

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Compounding 52

European Pharmaceutical Review

FEBRUARY 3, 2023

The facility forms two new fully-automated production lines for liquid and freeze-dried drugs, including highly potent compounds and advanced therapies such as antibody drug conjugates (ADCs). Positively, it comes at a time when securing fill finish capacity can be a challenge for many pharmaceutical companies.

Compounding 98

Compounding Dosage Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

DECEMBER 21, 2022

Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. So, when could the goal of a net zero pharmaceutical industry be achieved?

Compounding 97

Compounding Pharmaceutical Companies Pharmaceutical Companies Packaging 97

ISPE

MARCH 6, 2023

[link] A recent study published by My Green Lab 2 presented data from 74 biotechnology and pharmaceutical companies tracking the change in scope 1, 2, and 3 carbon intensity (measured in tons of CO2 emitted vs. the company’s revenue in USD) since 2015. For pharmaceutical companies, purchased goods (e.g.,

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Compounding 52